3rd generation glp 1 agonist Science Behind GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements Understanding the Next-Gen Weight Loss

Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting akt activation

In 2022, approximately 43% of adults were overweight, and 16% were classified as obese, representing nearly 890 million people worldwide, with rates having more than doubled since 1990

In the insulin group, therapeutic inertia was observed in 249 of 522 individuals (47.7%) (Table 6)

, this collection explores what it means to think, feel, and connect in the modern world

Semaglutide 2.4mg (marketed as Wegovy) represented the previous benchmark for injectable weight loss medications

GLP-1 and PPAR- agonist therapies were developed as novel approaches for the treatment of type 2 diabetes building on elegant studies of basic physiology